Phase I combination study of the PARP inhibitor veliparib plus carboplatin and gemcitabine in patients with advanced ovarian cancer and other solid malignancies

• Published in: Gynecologic oncology Vol. 148; no. 3; pp. 507 - 514
• Main Authors: Gray, Heidi J., Bell-McGuinn, Katherine, Fleming, Gini F., Cristea, Mihaela, Xiong, Hao, Sullivan, Danielle, Luo, Yan, McKee, Mark D., Munasinghe, Wijith, Martin, Lainie P.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.03.2018
• Subjects: BRCA1/2 mutations; Ovarian cancer; PARP inhibitor; Phase I; Veliparib; Phase I; BRCA1/2 mutations; Veliparib; PARP inhibitor; Ovarian cancer
• ISSN: 0090-8258; 1095-6859
• DOI: 10.1016/j.ygyno.2017.12.029

•Phase I study of veliparib+carboplatin/gemcitabine in advanced solid tumors.•MTD/RP2D was veliparib 250mg BID, carboplatin AUC 4, and gemcitabine 800mg/m2.•Thrombocytopenia and neutropenia were the most commonly reported AEs.•Promising antitumor activity in advanced solid tumors with germline BRCA mutations. Determine the maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of veliparib combined with carboplatin and gemcitabine in patients with advanced ovarian cancer and other nonhematologic malignancies. In this phase I study, patients with metastatic or unresectable solid tumors and ≤2 prior chemotherapy regimens received veliparib combined with carboplatin area under the curve (AUC) 4 on day 1 and gemcitabine 800mg/m2 on days 1 and 8 of a 21-day cycle for maximum 10cycles, followed by optional veliparib maintenance therapy. Veliparib dosing commenced twice-daily (BID) continuously on day 1 of cycle 2; granulocyte colony-stimulating factor was permitted. Dose escalation used a Bayesian continual reassessment method. Safety, tolerability, and efficacy were evaluated. Seventy-five patients were enrolled (ovarian cancer, n=54; breast cancer, n=12). Thirty-six patients with ovarian cancer (67%) had known germline BRCA mutations. Most common treatment-related adverse events (TRAEs; ≥60%) were thrombocytopenia, neutropenia, nausea, and anemia. Most common grade 3/4 TRAEs (≥40%) were neutropenia and thrombocytopenia. Dose-limiting toxicities were thrombocytopenia and neutropenia. The MTD/RP2D was established at veliparib 250mg with carboplatin AUC 4 plus gemcitabine 800mg/m2. Responses were observed in 69% of patients with BRCA-deficient ovarian cancer (45% partial, 24% complete responses). Five patients remained on veliparib (80–310mg BID) for >34cycles. Veliparib plus carboplatin/gemcitabine is tolerated, with a safety profile similar to carboplatin and gemcitabine alone. Combination therapy demonstrated promising preliminary antitumor activity in platinum-sensitive ovarian cancer patients with germline BRCA mutations. Trial registration ID: NCT01063816.